Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1α chemokine genes

International Journal of Cancer

Volumn 91, Issue 5, 2001, Pages 597-606

  Nomura, Tetsuhiko ^a   Hasegawa, Hitoshi ^a   Kohno, Masashi ^a   Sasaki, Miho ^a   Fujita, Shigeru ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Chemokines; Gene therapy

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FIBROSARCOMA; GENE EXPRESSION; GENETIC TRANSFECTION; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL DIVISION; CHEMOKINES, CC; CHEMOKINES, CXC; DISEASE PROGRESSION; FEMALE; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; KILLER CELLS, NATURAL; LEUKOCYTES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PHENOTYPE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035284176     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1107>3.0.CO;2-J     Document Type: Article

References (70)

1. Cancer vaccines
2. Advances in cancer immunotherapy
3. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
4. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2, a phase IB study
5. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
6. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
7. Granulocyte-macrophage colony-stimulating factor in metastatic renal cell carcinoma, a phase II trial
8. Chemokines: A new classification system and their role in immunity
9. Lymphotactin, a cytokine that represents a new class of chemokine
10. Molecular cloning and functional characterization of human lymphotactin
11. Migratory response of human natural killer cells to lymphotactin
12. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
13. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13
14. Identification and characterization of a novel beta chemokine containing six conserved cysteines
15. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7
16. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes
17. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells
18. Epstein-Barr virus-induced genes, first lymphocyte-specific G protein-coupled peptide receptors
19. + T cells
20. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
21. Cutting edge, differential regulation of chemokine receptors during dendritic cell maturation, a model for their trafficking properties
22. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells
23. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell location
24. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
25. Interleukin-2 in cancer treatment, disappointing or (still) promising? A review
26. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
27. Evidence that granulocyte-macrophage colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/ Langerhans cells in human lung and lung cancers
28. Dendritic cells and the control of immunity
29. + T cells
30. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12
31. Molecular cloning and structure of a pre-B-cell growth-stimulating factor
32. Unique structure of murine interleukin-2 as deduced from cloned cDNAs
33. Structure of the chromosomal gene for granulocyte-macrophage colony stimulating factor, comparison of the mouse and human genes
34. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice
35. Molecular cloning and expression of mouse homologue of SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily
36. Efficient selection for high-expression transfectants with a novel eukaryotic vector
37. Identification of single C motif-1/lymphotactin receptor XCR1
38. SFA-1, a novel cellular gene induced by human T-cell leukemia virus type 1, is a member of the transmembrane 4 superfamily
39. SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with alpha5beta1 integrin and regulates adhesion of human T cell leukemia virus type 1-infected T cells to fibronectin
40. + T cells in vivo
41. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer, perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
42. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
43. Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation
44. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
45. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
46. Papillary carcinoma of the thyroid: Hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells
47. + T lymphocytes
48. Molecular cloning of a novel C or gamma type chemokine, SCM-1
49. Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells
50. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo
51. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
52. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
53. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo
54. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
55. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
56. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
57. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells
58. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma
59. Cytokine regulation of tumour-associated macrophages
60. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes and granulocytes
61. Inhibition of in vivo tumor growth by the beta chemokine, TCA3
62. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo, role of immune cell subpopulations
63. Combined chemokine and cytokine gene transfer enhances antitumor immunity
64. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
65. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy
66. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity
67. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity
68. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
69. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
70. The CC chemokine 6Ckine binds to the CXC chemokine receptor CXCR3